PCRX240816C27500
- 1.51
- -0.02-1.31%
Pacira BioSciences Newsroom
Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
Should Value Investors Buy Pacira BioSciences (PCRX) Stock?
J.P. Morgan Maintains Pacira BioSciences(PCRX.US) With Buy Rating
Pacira BioSciences: Medicare and Medicaid Propose New Reimbursement for Exparel
Express News | Pacira BioSciences Announces Centers For Medicare And Medicaid Services Issued Proposed Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Rule For 2025; Proposes New Reimbursement For EXPAREL
Express News | Centers for Medicare and Medicaid Propose New Reimbursement for Exparel in All Outpatient Surgical Environments Beginning January 1, 2025
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
Express News | Pacira Biosciences Inc : RBC Cuts Target Price to $42 From $45
Top 5 Health Care Stocks That May Explode In July
Pacira BioSciences, Inc.'s (NASDAQ:PCRX) 30% Dip In Price Shows Sentiment Is Matching Revenues
Pacira Downgraded at Barclays Following Generic Exparel Approval
This Charter Communications Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
Pacira BioSciences Price Target Maintained With a $42.00/Share by Piper Sandler
Express News | Piper Sandler Maintains Overweight on Pacira BioSciences, Maintains $42 Price Target
Truist Financial Maintains Pacira BioSciences(PCRX.US) With Buy Rating
A Quick Look at Today's Ratings for Pacira BioSciences(PCRX.US), With a Forecast Between $25 to $57
Express News | Pacira Biosciences Shares Slip 1.1% Premarket After Barclays Cuts to Equal-Weight From Overweight
Express News | Pacira Biosciences : Barclays Cuts to Equal-Weight From Overweight
Express News | Pacira Biosciences : Barclays Cuts Target Price to $25 From $38
Barclays Downgrades Pacira BioSciences to Equalweight From Overweight, Adjusts Price Target to $25 From $38